priors.science/reviews/bispecific-antibodies-haematological-malignancy

Bispecific Antibodies Haematological Malignancy

The current evidence on 9 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

9claims tracked
53primary papers reviewed
4 Jun 2026latest evidence review
Weeklyre-scored against new papers
3 Established · 5 Likely · 1 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableTeclistamab in refractory multiple myelomaBcma MMEstablished86%8
StableMosunetuzumab complete response in follicular lymphomaCd20 FLEstablished85%9
StableCytokine release syndrome with bispecifics mostly low gradeBsab ToxEstablished85%8
StableGlofitamab complete response in large B-cell lymphomaCd20 DlbclLikely81%8
StableElranatamab in relapsed multiple myelomaBcma MMLikely78%9
StableBispecifics raise infection riskBsab ToxLikely77%8
StableTalquetamab targeting GPRC5D in multiple myelomaBcma MMLikely76%8
StableEpcoritamab response in large B-cell lymphomaCd20 DlbclLikely74%8
StableStep-up dosing lowers severe cytokine release syndromeBsab ToxUncertain61%8
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic